Register Login
Register to leave comments
  • News bot Jan. 6, 2026, 1:32 p.m.

    📋 Atossa Therapeutics, Inc. (ATOS) - Clinical Trial Update

    Filing Date: 2026-01-06

    Accepted: 2026-01-06 08:30:24

    Event Type: Clinical Trial Update

    Event Details:

    Atossa Therapeutics Inc. (ATOS) Announces Clinical Trial Update Atossa Therapeutics Inc. (ATOS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: application, endoxifen
    • Diseases/Conditions: metastatic ER+/HER2- Breast Cancer, unmet medical needs
    • Collaboration: Z)-Endoxifen(Z)-Endoxifen

    🔬 Clinical Development Pipeline (Atossa Therapeutics, Inc.):

    Product Type Development Stage Therapeutic Area Source
    (Z)-endoxifen DRUG Phase PHASE2 Breast Neoplasms ClinicalTrials.gov
    EMP-01 Placebo DRUG Phase PHASE2 Social Anxiety Disorder ClinicalTrials.gov
    EMP-01 DRUG Phase PHASE2 Social Anxiety Disorder ClinicalTrials.gov
    goserelin DRUG Phase PHASE2 Breast Neoplasms ClinicalTrials.gov
    MC2-25 vehicle DRUG Phase PHASE2 Vulvar Lichen Sclerosus ClinicalTrials.gov
    MC2-25 cream DRUG Phase PHASE2 Vulvar Lichen Sclerosus ClinicalTrials.gov
    VLS-01-BU Placebo DRUG Phase PHASE2 Treatment Resistant Depression ClinicalTrials.gov
    VLS-01-203 BU DRUG Phase PHASE2 Treatment Resistant Depression ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Atossa Therapeutics Inc.
    • CIK: 0001488039
    • Ticker Symbol: ATOS
    • Period End Date: 2026-01-06
    • Document Type: 8-K

Search

News categories